Physician profile
Stephen N Shoemaker
NPI 1780681262
$14,479.58
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,601 · 2020: $2,834 · 2021: $2,891 · 2022: $2,851 · 2023: $3,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,303.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,704.39 | 2019-2023 | Repatha, Evenity, Prolia |
| Pfizer INC. | $1,575.29 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,547.87 | 2019-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $1,520.82 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $866.81 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $848.69 | 2020-2023 | Qulipta, Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $742.80 | 2019-2023 | Synjardy, Stiolto Respimat, Tradjenta |
| Merck Sharp & Dohme LLC | $644.65 | 2019-2023 | Verquvo, Belsomra, Lagevrio |
| Amarin Pharma, INC. | $577.39 | 2019-2022 | |
| Glaxosmithkline, LLC. | $534.34 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $513.87 | 2019-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.47 | 2019-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $339.04 | 2019-2023 | |
| Abbott Laboratories | $338.90 | 2021-2023 | Freestyle Libre 2, Infinity, Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $269.66 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.